Study guide

3.10 Brachytherapy Principles, HDR, LDR & Isotopes

ARRT Radiation Therapy Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Patient Care & Education

1.1 Patient Assessment, History, and Vital Signs 1.2 Psychosocial Support & Coping Mechanisms 1.3 Patient & Family Education on Radiation Therapy 1.4 Radiation Side Effect Management: Skin & Mucosal Reactions 1.5 Radiation Side Effect Management: Systemic & Organ-Specific Side Effects 1.6 Nutritional Support & Management of Dysphagia/Odynophagia 1.7 Medical Emergencies in Radiation Oncology 1.8 Patient Rights, Informed Consent, and Advanced Directives 1.9 Ethical, Legal, and HIPAA Considerations for Radiation Therapists 1.10 Infection Control & Sterile Technique in Radiation Therapy 1.11 Transfer & Positioning Safety for Oncology Patients 1.12 Pharmacology & Contrast Media in Radiation Therapy 1.13 Cancer Epidemiology, Screening & Diagnostic Evaluation

2 Chapter 2: Radiation Physics, Radiobiology & Protection

2.1 Structure of Matter, Electromagnetic & Particulate Radiation 2.2 Radiation Production in Linear Accelerators & X-Ray Tubes 2.3 Photon & Electron Beam Interactions with Matter 2.4 Radiation Measurement Quantities, Units & Dosimeters 2.5 Radiation Protection Principles: ALARA, Time, Distance & Shielding 2.6 NCRP Dose Limits for Occupational & Public Exposure 2.7 Vault Design, Primary & Secondary Protective Barriers 2.8 Radiobiology Principles: Cell Survival Curves & Radiosensitivity (4 R's) 2.9 Linear Energy Transfer (LET) & Relative Biological Effectiveness (RBE) 2.10 Acute & Late Radiation Effects on Normal Tissues 2.11 Radiation Safety Rules, Emergency Procedures & Sealed Source Safety 2.12 MRI Magnetic Field Screening for Radiation Therapy Patients

3 Chapter 5: Treatment Sites, Tumors & Classification

5.1 Brain, Spinal Cord Tumors & Metastatic Patterns 5.2 Head & Neck Sites: Anatomy, Lymphatics & Patterns of Spread 5.3 Breast Cancer: Anatomy, Lymphatic Drainage & Radiation Considerations 5.4 Lung & Thoracic Tumors: Anatomy, Spread & Critical Structures 5.5 Abdomen, Pelvis, GI & GU Sites: Anatomy & Metastatic Patterns 5.6 Reproductive System Tumors: Prostate, Cervix & Related Sites 5.7 Lymphoma, Sarcoma, Skin, Leukemia & Oncologic Emergencies 5.8 Tumor Classification: Histopathology, Grade & Staging Systems

4 Chapter 3: Treatment Planning & Dosimetry

3.1 CT Simulation, Patient Positioning & Target Localization 3.2 Immobilization Devices & Radiopaque Marking Protocols 3.3 ICRU Target Volume Definitions (GTV, CTV, PTV, PRV, OAR) 3.4 Beam Modifiers: Wedges, Compensators, Bolus & MLC Systems 3.5 Depth Dose Characteristics: PDD, TMR, TPR & TAR Relationships 3.6 Monitor Unit (MU) Calculations & Clinical Dosimetry Formulas 3.7 3D Conformal Radiation Therapy (3D-CRT) Beam Arrangements 3.8 IMRT, VMAT & Inverse Planning Optimization Concepts 3.9 SRS, SBRT & Stereotactic Radiosurgery Techniques 3.10 Brachytherapy Principles, HDR, LDR & Isotopes 3.11 Dose Volume Histograms (DVH) & QUANTEC Tissue Tolerances

5 Chapter 4: Treatment Delivery, Image Guidance & QA

4.1 Pre-Treatment Chart Check & Plan Verification Protocols 4.2 Daily Patient Positioning, Setup Tolerances & Alignment Verification 4.3 Image-Guided Radiation Therapy (IGRT): Portal Imaging & CBCT Verification 4.4 Linear Accelerator Safety Systems, Interlocks & Gantry Controls 4.5 Special Techniques: TBI, TSI, SGRT & Gated Radiotherapy 4.6 Daily Linac Quality Assurance per AAPM TG-142 Specifications 4.7 Monthly & Annual Linac QA Requirements & Dosimetric Calibration 4.8 Patient-Specific IMRT QA & In-Vivo Dosimetry Verification 4.9 Machine Malfunctions, Override Protocols & Emergency Off Procedures 4.10 Record and Verify (R&V) Systems, EHR Integration & Treatment Documentation

3.10 Brachytherapy Principles, HDR, LDR & Isotopes

Key Takeaways Explain This Topic AI

Brachytherapy places sealed sources inside or adjacent to the tumor, using steep inverse-square falloff to raise target dose while limiting surrounding-tissue dose.

HDR versus LDR is defined by dose rate; exam emphasis is surrounding-tissue dose concepts and protection, not memorizing isotope half-lives or emission energies.

Basic applicator categories (intracavitary, interstitial, surface) matter for setup and protection awareness; ARRT states specific procedures are not covered in depth.

ARRT emphasizes basic brachytherapy uses, surrounding-tissue dose concepts, and radiation protection—not detailed isotope characteristic recall.

Remote afterloading and inventory/control practices reduce staff exposure compared with historical manual source handling.

Last updated: July 2026

Radiobiological Principles of Brachytherapy

Brachytherapy (derived from the Greek word brachys , meaning short-distance) involves placing sealed radioactive sources directly inside ( interstitial ), within body cavities ( intracavitary ), or on the skin surface ( surface mold ) adjacent to a tumor volume. [ Inverse Square Law ] [ Clinical Implantation Modes ]

  • Dose Rate ∝ 1 / r² • Interstitial: Seeds / Needles directly in tissue
  • High tumor dose + Steep dose falloff • Intracavitary: Tandem & Ovoids in body cavities
  • Spares adjacent normal tissues • Surface Mold: Custom plaque on skin / eye
  • The Inverse Square Law Advantage

Brachytherapy relies on the Inverse Square Law ( I ∝ 1 / r 2 I \propto 1/r^2 I ∝ 1/ r 2 ). Because radioactive sources are embedded directly inside or against the tumor, the dose rate is extremely high within the tumor but drops off exponentially with distance ( r r r ). This produces unparalleled normal tissue sparing.

Dose Rate Categories

Low Dose Rate (LDR): 0.4 to 2.0 Gy/hour 0.4\text{ to }2.0\text{ Gy/hour} 0.4 to 2.0 Gy/hour . Delivered continuously over several days (e.g., permanent prostate seeds, historical inpatient tandem & ovoids).

High Dose Rate (HDR): > 12.0 Gy/hour > 12.0\text{ Gy/hour} > 12.0 Gy/hour (typically 100 − 300 cGy/min 100 - 300\text{ cGy/min} 100 − 300 cGy/min ). Delivered in brief outpatient fractions lasting several minutes using a computerized remote afterloader.

Clinical Implantation Techniques

Interstitial Brachytherapy: Radioactive sources (seeds, wires, or hollow needles) are inserted directly into tumor tissue (e.g., permanent prostate seed implants, temporary breast implants, soft tissue sarcomas, base of tongue).

Intracavitary Brachytherapy: Applicators housing radioactive sources are placed inside anatomical body cavities near the tumor (e.g., Tandem and Ovoids / Tandem and Ring for cervical carcinoma, vaginal cylinder for endometrial cancer).

Surface Mold (Plaque) Brachytherapy: Radioactive sources are affixed to custom acrylic molds or eye plaques placed directly over superficial lesions (e.g., Iodine-125 plaques for ocular melanoma, custom skin molds).

  • Classical Dosimetry Systems: Manchester and Paris
  • 1. Manchester (Paterson-Parker) System

Developed for LDR implants to deliver a uniform dose (within ± 10 % \pm 10\% ± 10% ) across a target plane. Employs non-uniform source distribution, placing higher radioactive activity near the margins to counterbalance central dose falloff. Uterine Cavity

  • || <-- Central Tandem
  • ||
  • Point A --> * (2 cm Superior, 2 cm Lateral to Cervical Os)
  • /||\
  • Point B --> * / || \ * <-- Point B (5 cm Lateral to Midline)
  • ( || )
  • [Ovoid] [Ovoid]
  • Manchester Gynecologic Prescription Points

Point A: Located 2 cm superior to the external cervical os along the tandem, and 2 cm lateral to the uterine tandem. Represents the anatomical intersection of the uterine artery and ureter. Point A is the primary prescription point for cervical brachytherapy.

Point B: Located 2 cm superior to the os and 5 cm lateral to patient midline (3 cm lateral to Point A). Evaluates dose to obturator lymph nodes and pelvic side wall.

2. Paris System

Designed primarily for interstitial wire and line source implants (e.g., Iridium-192 wires). Mandates uniform source activity per unit length and uniform parallel source spacing. The prescription dose is specified as 85% of the basal dose (the average dose calculated at midpoints between radioactive sources).

Physical Characteristics of Radioactive Isotopes

ARRT exam note: Official Radiation Therapy content specifications state that only basic brachytherapy concepts are covered (including dose to surrounding tissue and radiation protection). Specific procedures and isotope characteristics are not covered. Use any isotope table below as clinical context only—not as a memorization checklist for the exam.

Radioactive source decay follows the exponential formula: A ( t ) = A 0 e − λ t = A 0 ( 0.5 ) t t 1 / 2 A(t) = A_0 e^{-\lambda t} = A_0 \left( 0.5 \right)^{\frac{t}{t_{1/2}}} A ( t ) = A 0 ​ e − λ t = A 0 ​ ( 0.5 ) t 1/2 ​ t ​

Where A 0 A_0 A 0 ​ is initial activity, λ = ln ⁡ 2 t 1 / 2 \lambda = \frac{\ln 2}{t_{1/2}} λ = t 1/2 ​ l n 2 ​ is the decay constant, and t 1 / 2 t_{1/2} t 1/2 ​ is physical half-life.

Focus for ARRT What to know

Surrounding-tissue dose Inverse-square falloff near sources protects adjacent organs relative to implanted/adjacent target dose

Radiation protection Time, distance, shielding, inventory, afterloader interlocks, and emergency retract procedures

Exam non-emphasis Exact isotope half-lives, emission energies, and procedure minutiae are outside ARRT’s stated scope

Iridium-192 ( 192 Ir ^{192}\text{Ir} 192 Ir ): Standard isotope for HDR remote afterloaders. A single high-activity (10 Ci / 370 GBq) seed attached to a drive cable moves through catheters. Replaced every 90 days (~3 months) due to its 73.83-day half-life.

Iodine-125 ( 125 I ^{125}\text{I} 125 I ): Standard low-energy isotope for permanent prostate seed implants ( t 1 / 2 = 59.4 days t_{1/2} = 59.4\text{ days} t 1/2 ​ = 59.4 days ).

Palladium-103 ( 103 Pd ^{103}\text{Pd} 103 Pd ): Short half-life isotope ( 17.0 days 17.0\text{ days} 17.0 days ) delivering a higher initial dose rate, preferred for high-grade or fast-growing prostate malignancies.

AAPM TG-43 Brachytherapy Dosimetry Formalism

AAPM Task Group 43 establishes the standard mathematical calculation for dose rate D ˙ ( r , θ ) \dot{D}(r, \theta) D ˙ ( r , θ ) at point ( r , θ ) (r, \theta) ( r , θ ) around a brachytherapy source: D ˙ ( r , θ ) = S K ⋅ Λ ⋅ G L ( r , θ ) G L ( r 0 , θ 0 ) ⋅ g L ( r ) ⋅ F ( r , θ ) \dot{D}(r, \theta) = S_K \cdot \Lambda \cdot \frac{G_L(r, \theta)}{G_L(r_0, \theta_0)} \cdot g_L(r) \cdot F(r, \theta) D ˙ ( r , θ ) = S K ​ ⋅ Λ ⋅ G L ​ ( r 0 ​ , θ 0 ​ ) G L ​ ( r , θ ) ​ ⋅ g L ​ ( r ) ⋅ F ( r , θ )

Where:

S K = S_K = S K ​ = Air-Kerma Strength of the source (in units of U = μ Gy ⋅ m 2 / h U = \mu\text{Gy}\cdot\text{m}^2/\text{h} U = μ Gy ⋅ m 2 / h ).

Λ = \Lambda = Λ = Dose Rate Constant in water at reference point ( 1 cm , 90 ∘ 1\text{ cm}, 90^\circ 1 cm , 9 0 ∘ ), in cGy / ( h ⋅ U ) \text{cGy}/(\text{h}\cdot U) cGy / ( h ⋅ U ) .

G L ( r , θ ) = G_L(r, \theta) = G L ​ ( r , θ ) = Geometry Factor accounting for spatial activity distribution (line vs point source model).

g L ( r ) = g_L(r) = g L ​ ( r ) = Radial Dose Function accounting for tissue absorption and scatter along the transverse axis.

F ( r , θ ) = F(r, \theta) = F ( r , θ ) = Anisotropy Function accounting for self-attenuation within encapsulation at oblique angles.

Remote Afterloader Safety Protocols

HDR remote afterloaders propel a single high-activity (10 Ci / 370 GBq) 192 Ir ^{192}\text{Ir} 192 Ir seed attached to a flexible drive cable through transfer tubes into implanted catheters under computerized stepper motor control.

NRC Mandated Safety Features

Emergency Manual Retract Crank: Mechanical hand crank mounted on the afterloader to manually draw the source back into the shielded tungsten safe if power or motor fails.

Door Interlocks: Automatically retracts the source instantly into the safe if the treatment room door opens.

Radiation Area Monitor: Independent wall-mounted Geiger monitor with battery backup confirming source retraction.

Emergency Equipment: Lead storage container (pig), long-handled forceps, and wire cutters kept inside the vault at all times.